These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24108558)

  • 21. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
    Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
    Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study.
    Hugonnet F; Fournier L; Medioni J; Smadja C; Hindié E; Huchet V; Itti E; Cuenod CA; Chatellier G; Oudard S; Faraggi M;
    J Nucl Med; 2011 Jul; 52(7):1048-55. PubMed ID: 21680694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
    Krajewski KM; Nishino M; Ramaiya NH; Choueiri TK
    AJR Am J Roentgenol; 2015 Mar; 204(3):W282-8. PubMed ID: 25714313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapies in renal cell cancer: recent developments in imaging.
    van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Boven E
    Target Oncol; 2010 Jun; 5(2):95-112. PubMed ID: 20625845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging in metastatic renal cell carcinoma.
    Griffin N; Gore ME; Sohaib SA
    AJR Am J Roentgenol; 2007 Aug; 189(2):360-70. PubMed ID: 17646462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
    de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM
    Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
    Krajewski KM; Franchetti Y; Nishino M; Fay AP; Ramaiya N; Van den Abbeele AD; Choueiri TK
    Oncologist; 2014 May; 19(5):507-14. PubMed ID: 24755461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stable disease in renal cell carcinoma after using signal transduction inhibitors.
    George S; Shah SN; Bukowski RM
    Rev Recent Clin Trials; 2010 May; 5(2):117-22. PubMed ID: 20199387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiological evaluation of response to treatment: application to metastatic renal cancers receiving anti-angiogenic treatment.
    Ammari S; Thiam R; Cuenod CA; Oudard S; Hernigou A; Grataloup C; Siauve N; Medioni J; Fournier LS
    Diagn Interv Imaging; 2014 Jun; 95(6):527-39. PubMed ID: 24906810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response evaluation criteria in solid tumors response of the primary lesion in metastatic renal cell carcinomas treated with sunitinib: does the primary lesion have to be regarded as a target lesion?
    Park I; Park K; Park S; Ahn Y; Ahn JH; Choi HJ; Jeong IG; Song C; Hong JH; Kim CS; Ahn H; Lee JL
    Clin Genitourin Cancer; 2013 Sep; 11(3):276-82. PubMed ID: 23332873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One decade of improving palliative care of metastatic renal cell carcinoma by antiangiogenic therapies: time to move toward RCC cure.
    Kroeger N; Zimmermann U; Burchardt M
    Int J Cancer; 2015 Apr; 136(7):1483-4. PubMed ID: 25230294
    [No Abstract]   [Full Text] [Related]  

  • 32. Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.
    Ranieri G; Marech I; Niccoli Asabella A; Di Palo A; Porcelli M; Lavelli V; Rubini G; Ferrari C; Gadaleta CD
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28891933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus.
    Cost NG; Delacroix SE; Sleeper JP; Smith PJ; Youssef RF; Chapin BF; Karam JA; Culp S; Abel EJ; Brugarolas J; Raj GV; Sagalowsky AI; Wood CG; Margulis V
    Eur Urol; 2011 Jun; 59(6):912-8. PubMed ID: 21367518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials.
    Schwartz LH; Mazumdar M; Wang L; Smith A; Marion S; Panicek DM; Motzer RJ
    Cancer; 2003 Oct; 98(8):1611-9. PubMed ID: 14534876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies.
    Schmidt N; Hess V; Zumbrunn T; Rothermundt C; Bongartz G; Potthast S
    Eur Radiol; 2013 Mar; 23(3):632-9. PubMed ID: 22918564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iodine quantification to distinguish clear cell from papillary renal cell carcinoma at dual-energy multidetector CT: a multireader diagnostic performance study.
    Mileto A; Marin D; Alfaro-Cordoba M; Ramirez-Giraldo JC; Eusemann CD; Scribano E; Blandino A; Mazziotti S; Ascenti G
    Radiology; 2014 Dec; 273(3):813-20. PubMed ID: 25162309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.
    Vercellino L; Bousquet G; Baillet G; Barré E; Mathieu O; Just PA; Desgrandchamps F; Misset JL; Hindié E; Moretti JL
    Cancer Biother Radiopharm; 2009 Feb; 24(1):137-44. PubMed ID: 19243256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma.
    Faria SC; Ng CS; Hess KR; Phongkitkarun S; Szejnfeld J; Daliani D; Charnsangavej C
    AJR Am J Roentgenol; 2007 Aug; 189(2):378-85. PubMed ID: 17646464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of central and local serial CT assessments of metastatic renal cell carcinoma patients in a clinical phase IIB study.
    Felsch M; Zaim S; Dicken V; Lehmacher W; Scheuring UJ
    Acta Radiol; 2017 Feb; 58(2):249-255. PubMed ID: 27083205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.